Quantum Pharmaceuticals
Quantum Pharmaceuticals is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!Subscription Options:
Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- albumin (1)
- antibiotics (1)
- antiviral (4)
- bioavailability (3)
- cancer (3)
- cardiotoxicity (1)
- collaboration (13)
- compound libraries (1)
- COPD (1)
- docking (12)
- drug design (4)
- drug discovery platform (1)
- druglikeness (4)
- false postive (3)
- flue (1)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (2)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- kinase (1)
- LD50 (2)
- logP (1)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (16)
- publications (10)
- q-Mol (1)
- QSAR (1)
- Quantum Software (10)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (18)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (3)
- Uncategorized (4)
- video (3)
- water (19)
Recent comments
- Talk@MIPT (in Russian) on Video recorded from "Water as a ferroelectric…" presentation at MIPT, November 5th, 2008
- FFT acceleration demonstration for (surface)GB methods on Water polarization charges in Generalized Born models.
- FFT acceleration demonstration for (surface)GB methods on O(N) Surface Charges Generalized Born calculation demonstration
- FFT acceleration demonstration for (surface)GB methods on O(N) SCGB solvation models: first “blood”
- FFT acceleration demonstration for (surface)GB methods on How to use Born surface charges to calculate solvation energy?
oncology Archive
-
Experimental siRNA complex uptake without transfection reagents
Posted on November 12, 2009 | View CommentsNormally siRNA do not penetrate cell membranes without transfection reagents. In Quantum Pharmaceutical we developed a new nanoscale complex with ability to transport siRNA over cell membranes of a cancer cell. In experiments with fluorescent siRNA molecules coupled with our proprietory transport system we conformed... -
Quantum Pharmaceuticals enters collaboration with Children’s Cancer Institute Australia
Posted on October 28, 2008 | View CommentsMoscow, October, 28 2008 Quantum Pharmaceuticals announce drug discovery collaboration with Children’s Cancer Institute Australia’s (CCIA). Under the terms of the agreement Quantum Pharmaceuticals gets access to CCIA in-house disease target data. Quantum Pharmaceuticals will contribute its technological breakthroughs and expertise in small molecule drug... -
Quantum Pharmaceuticals collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
Posted on September 12, 2008 | View CommentsQuantum Pharmaceuticals announce drug discovery collaboration with Fox Chase Cancer Center Under the terms of agreement Quantum Pharmaceuticals will apply its state-of-the-art in-house drug discovery technology to discover novel small molecule inhibitors in cancer area. The targets and financial terms were not disclosed. Fox Chase... -
Docking validation study: PDK1-kinase (oncology)
Posted on June 7, 2008 | View CommentsFollowing the classic thrombine study, we catch up with a more important target: PDK1 kinase. Pyruvate dehydrogenase kinase, isozyme 1, also known as PDK1, is a human gene.It codes for an isozyme of pyruvate dehydrogenase kinase (PDK).Pyruvate dehydrogenase (PDH) is a part of a mitochondrial...